Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2CNS 2

Conditions

Insulinoma 4Hypoglycemia 4Congenital Hyperinsulinism 4Neuroendocrine Tumors 3Neuroblastoma 3Hyperinsulinism 3Pheochromocytoma 2Parkinson Disease 2Carcinoid Tumor 2Thyroid cancer, medullary 1Parathyroid Neoplasms 1Paraganglioma 1Multiple Endocrine Neoplasia 1Lewy Body Disease 1Infant, Newborn, Diseases 1Hyperparathyroidism 1Hypercalcemia 1Glucose Metabolism Disorders 1Endocrine System Diseases 1Brain Neoplasms 1Beckwith-Wiedemann Syndrome 1

Interventions

fluorodopa F 18 2Tomography, Emission-Computed, Single-Photon 1Iodine-124 1Iodine-123 1Furosemide 1Clinical Laboratory Techniques 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Parkinson Disease × fluorodopa F 18 × Endocrine × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

NCT03042416 2022-01-10

18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

University of Alberta

Phase 3 Completed
400 enrolled
CNSEndocrineNET

Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡